Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B vaccine (recombinant) (Merck & Co.)
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
H-B-VAX II (also known as HBVaxII or Recombivax HB) is a recombinant hepatitis B vaccine developed and manufactured by Merck Sharp & Dohme (MSD). It is designed to prevent hepatitis B virus (HBV) infection across all age groups, including newborns, infants, children, adolescents, and adults. The vaccine contains purified recombinant hepatitis B surface antigen (HBsAg) produced in yeast (*Saccharomyces cerevisiae*) cells, which is adsorbed onto an amorphous aluminum hydroxyphosphate sulfate adjuvant. Upon intramuscular administration, the HBsAg stimulates the immune system to produce protective anti-HBs antibodies, conferring active immunity against all known subtypes of the hepatitis B virus.
- Brand names
- H-B-VAX IIHBVaxIIRecombivax HBHBVaxPro
- Other names
- hepatitis B vaccinerecombinant hepatitis B surface antigenHBsAg vaccinehepatitis B surface antigen (recombinant)
02
Targets
HBsAg antigenic loop
Beyond the preview
Go deeper on hepatitis B vaccine (recombinant) (Merck & Co.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B vaccine (recombinant) (Merck & Co.).